The changing treatment of metastatic her2-positive breast cancer

Area of Science:

• Oncology
• Medical Research

Background:

• HER2-positive breast cancer historically presents aggressive disease, distant metastasis, and poor prognosis.
• HER2-targeting therapies have significantly improved outcomes but resistance leads to disease progression, including central nervous system (CNS) metastases.

Purpose of the Study:

• To review current therapeutic options for HER2-positive metastatic breast cancer across different lines of treatment.
• To present novel agents under development for heavily pretreated patients and specific subgroups.

Main Methods:

• Literature review of existing and emerging therapies for HER2-positive metastatic breast cancer.
• Focus on treatment strategies for first-line, second-line, and subsequent treatment settings.
• Inclusion of data on novel agents and their efficacy in specific patient populations.

Main Results:

• Established HER2-targeting therapies offer improved outcomes but resistance necessitates further treatment lines.
• Novel agents show promise in heavily pretreated patients and in subgroups like HR-positive/HER2-positive tumors.
• Emerging therapies demonstrate potential for managing CNS metastases in HER2-positive breast cancer.

Conclusions:

• Despite advances, resistance to HER2-targeted therapies remains a significant clinical challenge in metastatic breast cancer.
• Ongoing development of novel agents offers new hope for patients with refractory disease and CNS involvement.
• Personalized treatment strategies are crucial for optimizing outcomes in HER2-positive metastatic breast cancer.